Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis

Keyphrases

• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Encephalitis 100%
• Murine Model 100%
• Neuroprotective Activity 100%
• Sodium Valproate 100%
• Valproate 83%
• Monocyte-derived Macrophages 50%
• Catenin 50%
• Tau Phosphorylation 33%
• Neurite Outgrowth 33%
• Severe Combined Immunodeficient Mice 33%
• Neurodegeneration 16%
• Neurotoxicity 16%
• HIV-associated Dementia 16%
• Cognitive Impairment 16%
• Gp120 16%
• Dementia 16%
• Disease Process 16%
• Therapeutic Potential 16%
• Neuronal Cell Bodies 16%
• Glial Activation 16%
• Protein Antigen 16%
• Infected People 16%
• Central Nervous System Infections 16%
• Adjunctive Therapy 16%
• Anti-neuroinflammation 16%
• Human Immunodeficiency virus-1 Infection 16%
• Glycogen Synthase Kinase 3 (GSK3) 16%
• Neuronal Dysfunction 16%
• Anticonvulsant 16%
• Behavioral Impairment 16%
• Microtubule-associated Protein 2 (MAP2) 16%
• Rat Cortical Neurons 16%
• Neuron-specific nuclear Protein 16%

Neuroscience

• Neuroprotective Agent 100%
• Human Immunodeficiency Virus 100%
• Encephalitis 100%
• Sodium Valproate 100%
• Macrophage 42%
• Catenin 42%
• HIV Associated Dementia 28%
• Neurite Outgrowth 28%
• Neurotoxicity 14%
• Nervous System 14%
• Microtubule Associated Protein 2 14%
• Adjuvant Therapy 14%
• Neurodegeneration 14%
• Glycogen Synthase Kinase 3 14%
• Anticonvulsant 14%
• Antigen 14%
• Neuron Specific Nuclear Protein 14%